NRG-GY035
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- NCT07198074 ↗
- Recruiting
- National Cancer Institute (NCI)
- Focused
We haven't built an HCP commentary report on NRG-GY035 (bevacizumab plus pembrolizumab; bevacizumab in pMMR, TP53-mutated advanced or recurrent endometrial cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NRG-GY035 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 3 | |
| X threads | 3 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Advanced Endometrial Carcinoma; Recurrent Endometrial Carcinoma
- Interventions
- Bevacizumab; Biospecimen Collection; Carboplatin; Computed Tomography; Magnetic Resonance Imaging; Paclitaxel; Pembrolizumab
- Arms
- Arm 1 (paclitaxel, carboplatin, pembrolizumab) · Active comparator
- Arm 2 (paclitaxel, carboplatin, bevacizumab) · Experimental
- Arm 3 (paclitaxel, carboplatin, pembrolizumab, bevacizumab) · Experimental
- Enrollment
- 255 (estimated)
- Primary outcomes
- Progression-free survival (PFS)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jan 27, 2026
- Primary completion
- Jul 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT07198074 · updated Nov 2, 2026